Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001867899
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer Kiniksa Pharmaceuticals International, plc

SEC File Number 001-38492

23 OLD BOND STREET, FLOOR 3

Address of Issuer LONDON

UNITED KINGDOM

WIS 4PZ

Phone 7814319100

Name of Person for Whose Account the Securities are To Be Sold

Tessari Eben

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Sacilitities
Class A Ordinary Shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	14000	255390.00	41566825	01/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of Person	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	from Whom	this	Donor	Securities	Payment	Payment *
	_	Transaction	Acquired		Acquired	Acquired		

a Gift?

Class A Ordinary Shares	09/16/2015 Founders Shares	Kiniksa Pharmaceuticals, Ltd	7000	09/16/2015 NA
Class A Ordinary Shares	01/13/2025 Employee Stock Option Exercise	Kiniksa Pharmaceuticals, Ltd	7000	Broker Payment 01/13/2025 for Cashless Exercise

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	10/15/2024	17000	456789.00
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	11/18/2024	17000	357641.00
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	12/16/2024	23017	470373.00

144: Remarks and Signature

Remarks
Date of Notice
01/13/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
04/29/2024
ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Eben Tessari

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)